Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs

Autor: Klaudia Meskova, Katarina Martonova, Patricia Hrasnova, Kristina Sinska, Michaela Skrabanova, Lubica Fialova, Stefana Njemoga, Ondrej Cehlar, Olga Parmar, Petr Kolenko, Vladimir Pevala, Rostislav Skrabana

Publikováno v: Antibodies, Vol 12, Iss 3, p 51 (2023)

Laboratory production of recombinant mammalian proteins, particularly antibodies, requires an expression pipeline assuring sufficient yield and correct folding with appropriate posttranslational modifications. Transient gene expression (TGE) in the s

Externí odkaz: https://doaj.org/article/828e9ecbcbb147f5ba172aba1385983b

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Autor: Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Norbert Zilka, Bengt Winblad, Michal Novak

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-16 (2018)

Abstract Background Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau prote

Externí odkaz: https://doaj.org/article/0a507430e9e248e6b42f67da7fb4aa06

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Autor: Norbert Zilka, Jozef Hanes, Branislav Kovacech, Martin Vyhnalek, Hlin Kvartsberg, Eva Kontsekova, Michal Novak, Oskar Hansson, Philip Scheltens, Kaj Blennow, Andrej Kovac, Eva Stevens, Henrik Zetterberg, Stanislav Katina, Charlotte E. Teunissen, Lubica Fialova, Jakub Hort, Lynn Boonkamp

Publikováno v: Neurology, 95(22), e3026-e3035. Lippincott Williams and Wilkins
Hanes, J, Kovac, A, Kvartsberg, H, Kontsekova, E, Fialova, L, Katina, S, Kovacech, B, Stevens, E, Hort, J, Vyhnalek, M, Boonkamp, L, Novak, M, Zetterberg, H, Hansson, O, Scheltens, P, Blennow, K, Teunissen, C E & Zilka, N 2020, ' Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias ', Neurology, vol. 95, no. 22, pp. e3026-e3035 . https://doi.org/10.1212/WNL.0000000000010814
Neurology
article-version (Version of Record) 3

ObjectiveTo investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls.MethodsWe developed and validated a novel Simoa immuno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef0d0d0cc734b774fd16f0321103a151
https://doi.org/10.1212/wnl.0000000000010814

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Autor: Duygu Tosun, Jozef Hanes, Branislav Kovacech, Tomas Hromadka, Lutz Froelich, Stanislav Katina, Lubica Fialova, Michal Prcina, Norbert Zilka, Andrej Kovac, Reinhold Schmidt, Eva Kontsekova, Martin Rakusa, Martin Cente, Carmen Prenn-Gologranc, Milica G. Kramberger, Stanislav Sutovsky, Peter Koson, Markus Otto, Stefan Ropele, Petr Novak, John Harrison, Michal Novak, Roman Sivak, Juraj Piestansky, Matej Ondrus, Jaroslav Galba, Miroslav Smisek, Maria Samcova, Eva Stevens, Jakub Hort, Bengt Winblad, Philip Scheltens, Vojtech Parrak, Peter Filipcik, Michal Fresser, Natalia Paulenka-Ivanovova

Publikováno v: Nature Aging, 1(6), 521-534. Springer
Novak, P, Kovacech, B, Katina, S, Schmidt, R, Scheltens, P, Kontsekova, E, Ropele, S, Fialova, L, Kramberger, M, Paulenka-Ivanovova, N, Smisek, M, Hanes, J, Stevens, E, Kovac, A, Sutovsky, S, Parrak, V, Koson, P, Prcina, M, Galba, J, Cente, M, Hromadka, T, Filipcik, P, Piestansky, J, Samcova, M, Prenn-Gologranc, C, Sivak, R, Froelich, L, Fresser, M, Rakusa, M, Harrison, J, Hort, J, Otto, M, Tosun, D, Ondrus, M, Winblad, B, Novak, M & Zilka, N 2021, ' ADAMANT : a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ', Nature Aging, vol. 1, no. 6, pp. 521-534 . https://doi.org/10.1038/s43587-021-00070-2

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9207a075a751b59f0b0c380b710aaf1
https://research.vumc.nl/en/publications/61abe2cc-82ad-4ac3-93be-d1cbc548881b

AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development

Autor: Branislav Kovacech, Norbert Zilka, Rostislav Skrabana, Monika Zilkova, Eva Kontsekova, Petr Novak, Michal Novak, Matej Ondrus, Lubica Fialova, Markus Otto

Publikováno v: The journal of prevention of Alzheimer's disease. 6(1)

Neurofibrillary tau protein pathology is closely associated with the progression and phenotype of cognitive decline in Alzheimer’s disease and other tauopathies, and a high-priority target for disease-modifying therapies. Herein, we provide an over

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9107b0b045dd794f369fdc83788c1864
https://pubmed.ncbi.nlm.nih.gov/30569088